Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
93.63 USD | -1.65% | +1.44% | +9.30% |
Apr. 04 | Haemonetics Gets FDA Clearance for New TEG 6s Global Hemostasis-HN Cartridge | MT |
Apr. 04 | Haemonetics Corporation Receives FDA Clearance for New TEG®? 6s Global Hemostasis - HN Cartridge | CI |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With an expected P/E ratio at 38.13 and 28.79 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.30% | 4.83B | B- | ||
-4.99% | 185B | C+ | ||
-0.97% | 109B | C | ||
-3.79% | 68.54B | A | ||
+3.64% | 51.74B | B- | ||
+9.16% | 45.22B | B- | ||
+3.12% | 41.74B | B+ | ||
+3.88% | 26.83B | A- | ||
+3.54% | 26.69B | B | ||
+11.62% | 25.63B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HAE Stock
- Ratings Haemonetics Corporation